This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.70% per year. These returns cover a period from January 1, 1988 through April 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
pot-stocks: Archive
Should SNDL Stock Be in Your Portfolio Post Q1 Earnings?
by Sundeep Ganoria
SNDL faces pressure after Q1 results show falling sales, weak cannabis demand, and margin strain, raising concerns about growth in a saturated Canadian market.
TLRYNegative Net Change ACBNegative Net Change SNDLNegative Net Change
marijuana medical pot-stocks
Schedule III for Some, Not All: Understanding the DOJ's Cannabis Shift
by Sundeep Ganoria
DOJ narrows cannabis reform, shifting select marijuana products to Schedule III while leaving broader federal restrictions intact.
GTBIFNegative Net Change CURLFNegative Net Change VRNONegative Net Change
marijuana medical pot-stocks
Cannabis Stock ACB Down 19% YTD: Should You Buy the Dip?
by Sundeep Ganoria
Aurora Cannabis stock has slid 19% YTD as competition and weak consumer cannabis weigh, but strong medical growth and rising margins could shape its next move.
TLRYNegative Net Change ACBNegative Net Change CURLFNegative Net Change
marijuana medical pot-stocks
Cannabis Operator VFF Stock Down 26% YTD: How to Play the Stock?
by Sundeep Ganoria
Village Farms' stock slides as U.S. headwinds and stiff competition weigh, but a 500% surge in international cannabis sales is reshaping its growth outlook.
TLRYNegative Net Change VFFNegative Net Change CURLFNegative Net Change
marijuana medical pot-stocks
Should Tilray Brands Be in Your Portfolio Post Q3 Earnings?
by Sundeep Ganoria
TLRY posts mixed Q3 with revenue growth and narrowing losses, as strong cannabis and distribution gains offset beverage weakness and rising competition.
CGCNo Net Change TLRYNegative Net Change ACBNegative Net Change CURLFNegative Net Change
marijuana medical pharmaceuticals pot-stocks
Cannabis Operator CRON Rises 46% in a Year: Time to Buy, Sell or Hold?
by Sundeep Ganoria
Cronos stock jumps 46% on strong international growth, margin expansion, and reform optimism; can the company sustain momentum amid rising competition?
CRONNegative Net Change TLRYNegative Net Change CURLFNegative Net Change
marijuana medical pot-stocks
Cannabis Operator GTBIF Stock Down 17% YTD: Should You Buy the Dip?
by Sundeep Ganoria
Green Thumb has lost 17% YTD as pricing pressure and competition weigh, but steady revenue growth and strong cash flow raise the question: Is the dip worth buying?
TLRYNegative Net Change GTBIFNegative Net Change CRLBFNegative Net Change
marijuana medical pot-stocks
Should Cresco Stock Be in Your Portfolio Post Q4 Earnings?
by Sundeep Ganoria
CRLBF faces US pricing pressure despite a Q4 sales beat and a strategic entry into Germany's cannabis market, raising questions about near-term upside.
CGCNo Net Change TLRYNegative Net Change CRLBFNegative Net Change
marijuana medical pot-stocks
Jazz Pharmaceuticals' CBD Drug Hits $1B: Time to Buy the Stock?
by Sundeep Ganoria
JAZZ CBD drug Epidiolex tops $1B in annual sales, boosting revenue visibility and cannabis exposure. Is the biotech's growth story just beginning?
JAZZNegative Net Change TLRYNegative Net Change ACBNegative Net Change
biotechs marijuana medical pot-stocks
SNDL Stock Loses 31% in Six Months: Should You Buy the Dip?
by Sundeep Ganoria
SNDL stock is down 31% in six months, but cannabis sales are up 16%, and free cash flow has turned positive. Can growth offset fierce competition?
TLRYNegative Net Change SNDLNegative Net Change CURLFNegative Net Change
marijuana medical pot-stocks